Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-03-14 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Regulatory Filings Classification · 99% confidence The document is explicitly titled 'FORM 6-K' and is filed by a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K is a periodic report required for foreign private issuers, which generally contains information that the company is required to disclose to its home country's securities regulator or stock exchange, or information that it makes public in press releases. The content is a press release announcing preclinical proof of concept data for a technology platform, which is typical for an unscheduled, material disclosure made via a 6-K filing. Since 'Form 6-K' is not one of the specific codes provided, and this document is a regulatory filing containing material, non-periodic information (a press release announcement), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it serves as a general category for miscellaneous SEC filings that don't fit the specific financial report types (like 10-K or IR). It is not an Earnings Release (ER) as it's not focused on period results, nor is it a specific report like an Audit Report (AR) or Interim Report (IR).
2024-03-14 English
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a '6K' filing format (which often corresponds to an 8-K filing in the US context for foreign private issuers). The core content states: 'Attached hereto is a report on*6K: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology* *ea0201801-6k_purplebioEDGAR1_Bannerless_isa.pdf*'. Since the document itself is short and primarily serves to announce the publication of an attached or linked report (the actual 6K/8-K content), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor a specific regulatory filing like DIRS or DIV. It is announcing the release of information.
2024-03-14 English
Corporate Presentation March 2024
Investor Presentation Classification · 95% confidence The document is a Form 6-K filed by a Foreign Private Issuer (Purple Biotech Ltd.) with the SEC. The core purpose of this filing, as stated in the text, is to announce that the registrant has made available an updated Company Presentation on its website, which is attached as Exhibit 99.1. The content of the exhibit is explicitly titled "Purple Biotech Corporate Presentation March 2024". This structure—a regulatory filing announcing the release of a presentation—fits the definition of an Investor Presentation (IP) being announced, but the filing itself is the mechanism of release. Since the document is a formal SEC filing (Form 6-K) whose primary function here is to disseminate a presentation, and given the detailed nature of the presentation content (pipeline, clinical data, MOA), the most appropriate classification for the *attached material* is Investor Presentation (IP). However, the filing itself is a Form 6-K, which is a general report for foreign private issuers. If the document were purely the presentation, it would be IP. If it were just an announcement of the presentation release without the presentation attached, it might lean towards RPA or RNS. Since the document *is* the Form 6-K that *includes* the presentation as an exhibit, and the presentation is the substantive content being delivered to investors, 'IP' is a strong candidate for the underlying material. Given the options, and recognizing that this is a formal SEC filing used to distribute investor materials, we must choose the best fit. The content is clearly an Investor Presentation. If the document were short and only announced the presentation, RPA would be better. Since the presentation content is embedded/attached and constitutes the bulk of the material, IP is the best fit for the information type being conveyed, even though the wrapper is a 6-K. The content is highly characteristic of an Investor Presentation (pipeline, clinical data, MOA slides).
2024-03-06 English
Corporate Presentation March 2024
Report Publication Announcement Classification · 98% confidence The document is very short (2087 characters) and explicitly states, "Attached hereto is a report on*6K:Purple Biotech Corporate Presentation March 2024* ea0201303-6k_purplebioEDGAR2_Bannerless_isa.pdf". This structure—a brief filing announcing the attachment or publication of a more detailed document (a Corporate Presentation)—fits the definition of a Report Publication Announcement (RPA). Although it references a 6-K filing structure, the content itself is the announcement wrapper, not the full presentation or the 6-K report content. Therefore, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2024-03-06 English
FORM 20F FOR 2023
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the U.S. Securities and Exchange Commission (SEC). Form 20-F is the standard annual report filing for foreign private issuers, equivalent to the 10-K for domestic U.S. companies. The text explicitly identifies itself as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2023, and includes a comprehensive table of contents covering financial information, management discussion, and governance. FY 2023
2024-03-05 English
FORM 20F FOR 2023
Report Publication Announcement Classification · 98% confidence The document is a filing notification submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The title explicitly states it is a 'Report of Periodic or Interim Report' under Israeli regulation. Crucially, the text states: 'Attached hereto is a report on *Annual report for 2023 on form 20F*'. Since the document itself is very short (2135 chars) and serves only to announce the publication and attachment of the actual Annual Report (Form 20-F), it falls under the 'Report Publication Announcement' category (RPA) based on the 'MENU VS MEAL' rule. Although the attached document is an Annual Report (which would typically be 10-K for US filers, but here it's a 20-F filed by a foreign private issuer), this specific filing is the *announcement* of that report.
2024-03-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.